FAQ

1592U89

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1996-2002
02419962002

Related topics

Related topics

2 relations

Broader (2)

abacavirabacavir sulfate

Related mentions per year

Related mentions per year

1996-2018
1990200020102020
1592U89
abacavir
abacavir sulfate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2000
2000
Pharmacokinetic interaction of abacavir (1592U89) and ethanol in human immunodeficiency virus-infected adults.
While in vitro results at clinically relevant concentrations do not predict abacavir (1592U89) interactions with drugs highly… (More)
Is this relevant?
2000
2000
Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group.
Abacavir (1592U89) is a nucleoside inhibitor of human immunodeficiency virus (HIV) type 1 reverse transcriptase (RT). Resistance… (More)
Is this relevant?
2000
2000
Population pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjects.
Abacavir (formerly 1592U89) is a carbocyclic nucleoside analog with potent anti-human immunodeficiency virus (anti-HIV) activity… (More)
Is this relevant?
1999
1999
Safety and single-dose pharmacokinetics of abacavir (1592U89) in human immunodeficiency virus type 1-infected children.
Abacavir (formerly 1592U89) is a potent 2'-deoxyguanosine analog reverse transcriptase inhibitor that has been demonstrated to… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
1999
1999
Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection.
Abacavir (1592U89), a nucleoside reverse transcriptase inhibitor with in vitro activity against human immunodeficiency virus type… (More)
Is this relevant?
1999
1999
Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adults.
Abacavir (1592U89) is a nucleoside analog reverse transcriptase inhibitor that has been demonstrated to have selective activity… (More)
Is this relevant?
1998
1998
Nucleoside analog 1592U89 and human immunodeficiency virus protease inhibitor 141W94 are synergistic in vitro.
The use of combinations of anti-human immunodeficiency virus (anti-HIV) agents targeted to different molecular targets will most… (More)
Is this relevant?
1997
1997
1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity.
1592U89, (-)-(1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclo pentene-1-methanol, is a carbocyclic nucleoside with… (More)
Is this relevant?
1997
1997
Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89.
The anabolism of 1592U89, (-)-(1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclo pentene-1-methanol, a selective… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 2
Is this relevant?
1997
1997
Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89.
The carbocyclic nucleoside 1592U89 is a selective inhibitor of the human immunodeficiency virus (HIV), targeting the reverse… (More)
Is this relevant?